NCT02052908View on ClinicalTrials.gov

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 27, 2014

Primary Completion Date

October 25, 2019

Study Completion Date

January 5, 2021

Conditions

Lynch Syndrome

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Naproxen

Given PO

OTHER

Placebo Administration

Given PO

Trial Locations (4)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

77030

M D Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02052908 - Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome | Biotech Hunter | Biotech Hunter